Herriot Tabuteau, M.D., the CEO of Axsome Therapeutics, brings a unique blend of medical expertise and business acumen to his role. With an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School, he has a strong...

Herriot Tabuteau, M.D., the CEO of Axsome Therapeutics, brings a unique blend of medical expertise and business acumen to his role. With an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School, he has a strong foundation in both medicine and management. Dr. Tabuteau founded Axsome Therapeutics in 2012 and has been steering its growth ever since. Under his leadership, the company focuses on developing novel therapies for serious central nervous system disorders. His commitment to the mission is evident in the way he has structured the company's performance-based compensation system, which aligns executives' pay with the company’s success. Notably, in 2022, he received over $1.3 million in total compensation, a testament to his significant contributions to the company's achievements. Outside of his work at Axsome, he also founded Antecip Capital, emphasizing his deep involvement in the biotech industry. With a birthday in June 1975, he continues to be at the forefront of innovation in the medical field while pushing Axsome towards impactful drug development.